Mitigation of intrahepatic cholestasis induced by 17α-ethinylestradiol via nanoformulation of Silybum marianum L.

Table 5 Effect of SM or Nano SM on serum biochemical makers

Animal groups	ALT (IU/mL)	AST (IU/mL)	ALP (IU/mL)	Total Bilirubin (mg/dL)	Direct Bilirubin (mg/dL)
Normal	67.23 ± 4.27	133.68 ± 5.78	80.01 ± 1.42	0.51 ± 0.05	0.17 ± 0.03
EE	158.07 ± 4.23^a	240.22 ± 13.75^a	176.86 ± 6.55^a	4.07 ± 0.29^a	1.68 ± 0.22^a
EE + UDCA	95.20 ± 7.88^ab	159.58 ± 15.00^b	85.65 ± 4.00^b	1.13 ± 0.07^b	0.39 ± 0.07^b
EE + SM	102.99 ± 6.8^ab	197.99 ± 17.10^ab	124.04 ± 6.05^abc	1.98 ± 0.17^abc	1.22 ± 0.23^abc
EE + Nano SM	82.30 ± 2.95^b	150.07 ± 4.29^b	81.74 ± 5.19^bcd	1.10 ± 0.12^bcd	0.36 ± 0.07^bcd

The results are presented as means ± SE. ^{a, b, c. d} Significant difference from normal, EE, EE + UDCA, and EE + SM groups at p < 0.05, respectively. ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; EE: 17α-ethinylestradiol; UDCA: ursodeoxycholic acid; SM: Silybum marianum L

ISSN: 2662-7671